Arthneeti
Shree Ganesh Remedies Ltd Q1 FY27 results are out (Apr–Jun 2026) →See revenue, profit and what management said. You are viewing Q1 FY26.
SG

Shree Ganesh Remedies Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Q1 FY26: Revenue ₹24.67 Cr, PAT ₹3.44 Cr

Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹25Cr
−0.4% YoY
Net profit
₹3Cr
−25.8% YoY
Margin
29.59%
−3.2 pp YoY

Based on Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹677
Market cap₹896 Cr
P/E58.0

The short version

Q1FY26 Revenue from Operations: ₹24.67 crores - Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25) - Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02% - Q1FY26 EBITDA (excluding other income & exceptional items): ₹7.30 crore - Q1FY26 EBITDA margin: 29.6% (down 321 bps YoY) - Q1FY26 PAT: ₹3.44 crore (down 26.09% YoY) - YoY changes: - EBITDA down 10.19% - PAT down 26.09% - Revenue from operations nearly flat, -0.45% YoY - Explicit margin outlook: - Presentation states EBITDA margins have moderated to a "more normalised and sustainable level" compared to elevated margins seen in prior year, implying margins are expected to stabilize at current levels rather than improve sharply in near term.

From Shree Ganesh Remedies Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1FY26 Revenue from Operations: ₹24.67 crores
  • Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25)
  • Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02%
  • Outlook: Management notes a moderation in growth due to contract repricing in the CRAMS business, European market headwinds, and domestic competition.

2 more points from Shree Ganesh Remedies Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Dahej Land Acquisition: 40,554 sq m acquired in 2022 for ₹11 crores; construction of common infrastructure and warehousing initiated; phased expansion planned; multiple projects under evaluation (Page 15).
  • Ankleshwar Site Unit 1: Completed Plant 8 CAPEX in FY25; ongoing CAPEX for Plant 7 estimated at ₹15 crores, commissioning expected in FY26; Block 7 design completed and construction accelerated (Pages 13, 32).
  • New Pilot Facility: Establishing a pilot plant to expedite execution; slated for completion within Q1FY26 (Page 32).

2 more points from Shree Ganesh Remedies Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pharmaceuticals
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides qualitative insights related to orders and project pipeline: - The Q1FY26 performance was affected by contract repricing in the CRAMS business, indicating ongoing contract management. - The company is actively engaged in multiple new projects with both established and marquee clients, strengthening the future growth pipeline.

2 more points from Shree Ganesh Remedies Ltd's call on order book

Create a free account to keep reading this call

Shree Ganesh Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Shree Ganesh Remedies Ltd Q1 FY26 results — key figures

Shree Ganesh Remedies Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue2525-0.4%24+1%
Operating profit (EBITDA)78-10.2%10-26.1%
Operating margin29.59%32.81%-3.2 pp40.44%-10.8 pp
Profit before tax56-27.3%9-47.7%
Net profit (PAT)35-25.8%7-47.7%
EPS (₹)2.693.62-25.7%5.14-47.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Shree Ganesh Rem's management said in earlier quarters

Earlier calls (1)

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Shree Ganesh Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Shree Ganesh Remedies Ltd Q1 FY26 results?

Q1FY26 Revenue from Operations: ₹24.67 crores - Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25) - Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02% - Q1FY26 EBITDA (excluding other income & exceptional items): ₹7.30 crore - Q1FY26 EBITDA margin: 29.6% (down 321 bps YoY) - Q1FY26 PAT: ₹3.44 crore (down 26.09% YoY) - YoY changes: - EBITDA down 10.19% - PAT down 26.09% - Revenue from operations nearly flat, -0.45% YoY - Explicit margin outlook: - Presentation states EBITDA margins have moderated to a "more normalised and sustainable level" compared to elevated margins seen in prior year, implying margins are expected to stabilize at current levels rather than improve sharply in near term.

What is Shree Ganesh Remedies Ltd share price analysis?

Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.

Is Shree Ganesh Remedies Ltd planning capital expenditure?

Dahej Land Acquisition: 40,554 sq m acquired in 2022 for ₹11 crores; construction of common infrastructure and warehousing initiated; phased expansion planned; multiple projects under evaluation (Page 15).

Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.